Anonymousabout 3 hours ago
U.S. cancer clinics are racing to enroll patients in an expanded access program for daraxonrasib, a Revolution Medicines drug that nearly doubled median overall survival in previously treated metastatic pancreatic cancer in a Phase 3 trial. The FDA authorized the expanded access protocol within two days of receiving the application, but questions remain about equitable access, manufacturing capacity, financial conflicts of interest, and whether the roughly 90% of pancreatic cancer patients with KRAS mutations can realistically be served in the first year after potential approval.